5-Amino-3-methylthiophene-2-carboxylic acid | 1368185-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-Amino-3-methylthiophene-2-carboxylic acid
• CAS: 1368185-04-9
• 化学式: C₆H₇NO₂S
• 分子量: 157.19
• InChiKey: WAAXJDMUBWOSAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  91.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT D'UNE MALADIE GÉNÉTIQUE
  申请人：DESIGN THERAPEUTICS INC

  公开号：WO2021158707A1

  公开（公告）日：2021-08-12

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

  本公开涉及化合物和方法，用于调节dmpk的表达，并治疗dmpk发挥积极作用的疾病和病况。该化合物可以是一种转录调节分子，具有第一末端、第二末端和寡聚骨架，其中：a）第一末端包括一种DNA结合基团，能够非共价结合到核苷酸重复序列CAG或CTG；b）第二末端包括结合到调节分子的蛋白结合基团，该调节分子调节包含核苷酸重复序列CAG或CTG的基因的表达；c）寡聚骨架包括连接第一末端和第二末端的连接物。
• [EN] SMALL MOLECULE INHIBITOR OF 3-PHOSPHOGLYCERATE DEHYDROGENASE AND USES THEREOF<br/>[FR] INHIBITEUR À PETITES MOLÉCULES DE LA 3-PHOSPHOGLYCÉRATE DÉSHYDROGÉNASE ET SES UTILISATIONS
  申请人：CANTLEY LEWIS C

  公开号：WO2017117532A1

  公开（公告）日：2017-07-06

  Embodiments of the present invention are directed to small molecule inhibitors of PHGDH. Other embodiments of the present invention relate to methods of treating cancers using the small molecule inhibitors of PHGDH disclosed herein. Still other embodiments of the present invention relate to methods for using the small molecule inhibitors of PHGDH to study serine metabolism.

  本发明实施例涉及对PHGDH的小分子抑制剂。本发明的其他实施例涉及使用此处披露的PHGDH小分子抑制剂治疗癌症的方法。本发明的另一实施例涉及使用PHGDH的小分子抑制剂研究丝氨酸代谢的方法。
• ORGANIC COMPOUNDS
  申请人：Dales Natalie

  公开号：US20100233116A1

  公开（公告）日：2010-09-16

  The present invention provides heterocyclic derivatives hat modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了能够调节硬脂酰辅酶A脱饱和酶活性的杂环衍生物。本发明还涵盖了使用这种衍生物来调节硬脂酰辅酶A脱饱和酶活性的方法，以及包含这种衍生物的药物组合物。
• [EN] METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR MODULER UNE DYSTROPHIE MYOTONIQUE DE TYPE 1
  申请人：DESIGN THERAPEUTICS INC

  公开号：WO2022126000A1

  公开（公告）日：2022-06-16

  The present disclosure relates to transcription modulator molecule compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The transcription modulator comprising a) the first terminus comprising a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) a second terminus comprising a protein-binding moiety capable of binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) an oligomeric backbone comprising a linker between the first terminus and the second terminus.

  本公开涉及转录调节分子化合物和调节dmpk表达的方法，以及治疗dmpk发挥积极作用的疾病和病症的方法。所述转录调节剂包括a）第一端包括DNA结合基团，能够非共价地结合到核苷酸重复序列CAG或CTG上；b）第二端包括蛋白结合基团，能够结合到调节分子上，该调节分子调节包括核苷酸重复序列CAG或CTG的基因的表达；以及c）寡聚骨架，包括连接第一端和第二端的连接物。
• SUBSTITUIERTE OXOPYRIDIN-DERIVATE
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3197889A1

  公开（公告）日：2017-08-02